Lv2
130 积分 2024-10-24 加入
Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines
1天前
已完结
Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy
1天前
已完结
Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy
1天前
已完结
Preclinical <i>in vitro</i> evaluation of immune suppression induced by GYM329, Fc-engineered sweeping antibody
13天前
已完结
Daratumumab for multidrug-resistant phospholipase-A2 receptor–related membranous nephropathy
15天前
已完结
Updated diagnostic and therapeutic management for membranous nephropathy
22天前
已完结
Updated diagnostic and therapeutic management for membranous nephropathy
27天前
已完结
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy
30天前
已完结
Changing treatment paradigms for membranous nephropathies
1个月前
已完结
Membranous nephropathy: new pathogenic mechanisms and their clinical implications
1个月前
已完结
皖公网安备34019202002308
